Beta‐interferon exposure and onset of secondary progressive multiple sclerosis

BACKGROUND AND PURPOSE: Beta‐interferons (IFNβ) are the most widely prescribed drugs for patients with multiple sclerosis (MS). However, whether or not treatment with IFNβ can delay secondary progressive MS (SPMS) onset remains unknown. Our aim was to examine the association between IFNβ exposure an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, T., Shirani, A., Zhao, Y., Karim, M. E., Gustafson, P., Petkau, J., Evans, C., Kingwell, E., van der Kop, M., Zhu, F., Oger, J., Tremlett, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008210/
https://www.ncbi.nlm.nih.gov/pubmed/25846809
http://dx.doi.org/10.1111/ene.12698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008210/
https://www.ncbi.nlm.nih.gov/pubmed/25846809
http://dx.doi.org/10.1111/ene.12698

Ejemplares similares